# Pizarra — PT-pseudo_2b3ef1d3a505 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2b3ef1d3a505
Task: 1

Encounter: Urology - outpatient on 23 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.06 ng/mL²
  - PSA velocity: 0.66 ng/mL/yr
  - Prior PSA: 3.7 ng/mL
  - Prostate volume: 69.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81166416 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.

Vitals: weight 66 kg, height 185 cm, BMI 19.3, BP 113/72 mmHg, HR 74 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2015).

Chief complaint: Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review.

History: A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management.

Physical examination: DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 31 units / week (heavy); exercise Light weight-training at home, 2x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.45 +/- 0.20   (95% CI 0.10-0.83)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 6.6 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=4.2, age=67.0, psad=0.06, dre_ord=1.0, vol=69.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.66 ng/mL/yr) and the specific PI-RADS 5 score in conjunction with the prior positive biopsy status (which implies a known history of cancer, even if the prior result was ISUP Grade Group 1). It also missed the context provided by the PSA history trend (climb from 2.5 to 4.2 ng/mL) and the DRE finding of a "Nodus," which are crucial clinical context points not fully captured by the static panel variables.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.45 +/- 0.20). This wide interval suggests the classifier is genuinely uncertain. A failure mode is that the prior ignores the high PI-RADS 5 score and the rising PSA velocity, which strongly push towards a positive biopsy recommendation. Another failure mode is that the prior does not adequately weigh the history of a prior positive biopsy, which might suggest a need for surveillance rather than immediate re-biopsy, contradicting the high risk score.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant suspicious features beyond the PI-RADS 5 score, it would increase the likelihood of biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid, concerning rise, it would increase the likelihood of biopsy.
  <document> previous GP / urology consultation notes -> These notes might clarify the clinical significance of the prior ISUP Grade Group 1 result and the LUTS severity.
  <document> laboratory panel -> This panel might provide context on other markers that influence the risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units and dates. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_2b3ef1d3a505", "radiology_report": "Subject: Multiparametric MRI of the Prostate | Institution: Ziekenhuis Gelderse Vallei, Ede | Date: 15 January 2025\n\nClinical indication: Assessment of an elevated prostate-specific antigen level of 4.2 ng/mL alongside a history of a previously positive biopsy.\n\nFINDINGS:\nThe gland measures 69.0 mL. High b-value DWI sequences highlight marked restricted diffusion, corroborated by correspondingly low ADC values, within a focal hypointense abnormality measuring roughly 18 x 15 x 12 mm situated at the mid-gland level of the right peripheral zone. Dynamic contrast-enhanced imaging captures early, focal enhancement. The neurovascular bundles remain intact. No definitive extraprostatic extension or seminal vesicle invasion is apparent.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right mid-peripheral zone. Prostate volume 69.0 mL. PSAD 0.06 ng/mL/mL. csPCa predicted probability 0.81166416."}

  **psa_trend**
  {"case_id": "PT-pseudo_2b3ef1d3a505", "psa_trend": [{"date": "Jun 2023", "val": 0.8}, {"date": "Dec 2023", "val": 2.2}, {"date": "Jul 2024", "val": 0.7}, {"date": "Jan 2025", "val": 4.2}]}

  **previous_notes**
  {"case_id": "PT-pseudo_2b3ef1d3a505", "previous_notes": [{"date": "29 Jan 2024", "author": "Dr. R. Visser (GP)", "text": "A December 2023 reading of 3.0 ng/mL triggered a follow-up test to monitor the rising trend. The patient received lifestyle guidance, with documentation noting a 4.0 ng/mL assessment threshold."}, {"date": "02 Aug 2023", "author": "Dr. R. Visser (GP)", "text": "An initial measurement of 2.5 ng/mL sparked a differential between benign enlargement and early malignancy. A subsequent PSA check was booked for mid-2024, coinciding with standard health screenings."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_2b3ef1d3a505", "laboratory_results": [{"name": "PSA", "val": "4.2 ng/mL", "date": "09 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.88 ng/mL", "date": "09 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "21%", "date": "09 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "16.0 g/dL", "date": "09 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.2 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "221 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "82 umol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "09 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "8.3 nmol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "97 U/L", "date": "09 Dec 2024", "flag": ""}, {"name": "LDH", "val": "196 U/L", "date": "09 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the right mid-peripheral zone
  PSA velocity of 0.66 ng/mL/yr
  PSA trend shows a rise from 2.5 ng/mL (Aug 2023) to 4.2 ng/mL (Jan 2025)
  Prior biopsy was positive

  AGAINST sampling this patient now:
  Prior biopsy was positive (suggesting known history)

WHERE THIS LEANS
  The retrieved evidence strongly argues for sampling due to the high PI-RADS 5 score and the concerning PSA velocity/trend, which contradicts the statistical prior of 'NO BIOPSY'.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports sampling due to the high PI-RADS 5 lesion in the right mid-peripheral zone and the concerning PSA velocity of 0.66 ng/mL/yr. This finding is further supported by the rising PSA trend from 2.5 ng/mL to 4.2 ng/mL and the fact that the prior biopsy was positive, necessitating re-evaluation of the current status.

Variables that carried weight: bx=decisive, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
